S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:EYES - Second Sight Medical Products Stock Price, Forecast & News

$1.14
-1.20 (-51.28 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$1.00
Now: $1.14
$2.53
50-Day Range
$2.18
MA: $4.27
$5.98
52-Week Range
$1.81
Now: $1.14
$9.60
Volume1.11 million shs
Average Volume42,705 shs
Market Capitalization$17.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.
Read More
Second Sight Medical Products logo

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.38 million
Book Value$0.47 per share

Profitability

Net Income$-33,590,000.00
Net Margins-994.14%

Miscellaneous

Employees123
Market Cap$17.85 million
Next Earnings Date5/20/2020 (Estimated)
OptionableOptionable

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.


Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

How has Second Sight Medical Products' stock been impacted by COVID-19 (Coronavirus)?

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EYES shares have decreased by 67.7% and is now trading at $1.14. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Second Sight Medical Products?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Second Sight Medical Products.

When is Second Sight Medical Products' next earnings date?

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Second Sight Medical Products.

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) announced its earnings results on Thursday, March, 19th. The medical device company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.01. The medical device company had revenue of $0.50 million for the quarter, compared to analysts' expectations of $0.83 million. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 183.76%. View Second Sight Medical Products' earnings history.

What price target have analysts set for EYES?

2 equities research analysts have issued 1 year price targets for Second Sight Medical Products' shares. Their forecasts range from $2.00 to $2.50. On average, they expect Second Sight Medical Products' share price to reach $2.25 in the next twelve months. This suggests a possible upside of 97.4% from the stock's current price. View analysts' price targets for Second Sight Medical Products.

Has Second Sight Medical Products been receiving favorable news coverage?

Media stories about EYES stock have been trending very positive on Monday, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the medical device company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSecond Sight Medical Products.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Opko Health (OPK), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), TransEnterix (TRXC), Plug Power (PLUG) and Canopy Growth (CGC).

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)
  • Mr. John T. Blake, CFO & Corp. Sec. (Age 43)
  • Mr. William Patrick Ryan, Chief Operating Officer (Age 58)
  • Gunnar Bjorg, Founder
  • Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sigma Planning Corp (2.43%) and B. Riley Wealth Management Inc. (0.23%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland. View institutional ownership trends for Second Sight Medical Products.

Which institutional investors are selling Second Sight Medical Products stock?

EYES stock was sold by a variety of institutional investors in the last quarter, including Sigma Planning Corp, and B. Riley Wealth Management Inc.. Company insiders that have sold Second Sight Medical Products company stock in the last year include Edward David Randolph, and Jonathan Will Mcguire. View insider buying and selling activity for Second Sight Medical Products.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $1.14.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $17.85 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe. View additional information about Second Sight Medical Products.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is http://www.secondsight.com/.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]


MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  251 (Thanks for Voting!)
Underperform Votes:  271 (Thanks for Voting!)
Total Votes:  522
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel